Previous close | 297.13 |
Open | 298.51 |
Bid | 293.55 x 800 |
Ask | 300.00 x 800 |
Day's range | 295.34 - 299.11 |
52-week range | 188.54 - 319.74 |
Volume | |
Avg. volume | 907,796 |
Market cap | 43.229B |
Beta (5Y monthly) | 0.19 |
PE ratio (TTM) | 14.11 |
EPS (TTM) | 21.16 |
Earnings date | 18 Jul 2023 - 24 Jul 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 332.26 |
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysts are bullish on Biogen's Alzheimer's drug, Leqembi, projecting it may generate over $10 billion in sales at its peak.
Key Insights Biogen's estimated fair value is US$394 based on 2 Stage Free Cash Flow to Equity Biogen's US$306 share...
Biogen (BIIB) is set to launch three potential new drugs across four indications in 2023, all in areas of high unmet need.
Eli Lilly (NYSE: LLY) and Biogen (NASDAQ: BIIB) are both keen to compete in the market for Alzheimer's disease therapies. Biogen's prior attempt at an Alzheimer's medicine to hit the market was a train wreck, but its latest drug seems to be avoiding a repeat. Meanwhile, Eli Lilly has yet to submit its candidate for regulatory review.
The stock has been rallying but how it performs from here will likely depend on the fate of its Alzheimer's treatment, Leqembi.
Eli Lilly stock may look expensive, but there's still plenty of value here for long-term investors.
Passive investing in index funds can generate returns that roughly match the overall market. But you can significantly...
Denali (DNLI) delivers a wider Q1 loss while collaboration revenues surpass estimates.
Ionis (IONS) reports a narrower-than-expected Q1 loss. Sales come in line with estimates. The company re-affirms its previously issued financial guidance for 2023.
Biogen's (NASDAQ:BIIB) stock is up by a considerable 12% over the past month. As most would know, fundamentals are what...
Eli Lilly stock is up on news that its new Alzheimer's drug showed reduction in cognitive decline.
Key Insights Institutions' substantial holdings in Biogen implies that they have significant influence over the...
Yahoo Finance’s Anjalee Khemlanin joins the Live show to discuss quarterly earnings for Abbvie, Merck & Company, and Biogen, the headwinds facing drugmakers, and what they mean for investors watching the pharmaceuticals space.
Biogen, Incyte, Morphic Therapeutic and bluebird bio are included in this Analyst Blog.
Earnings and pipeline updates from Biogen (BIIB) and Arrowhead (ARWR) are they key highlights of the biotech sector.
Biogen (BIIB) beats first-quarter estimates for earnings and sales. It maintains its 2023 guidance. Stock drops in pre-market trading.
The headline numbers for Biogen Inc. (BIIB) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Biogen Inc. (BIIB) delivered earnings and revenue surprises of 4.62% and 5%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Biogen Inc said on Tuesday it will pause or discontinue at least four studies of experimental drugs to focus on more potentially lucrative options including its second Alzheimer's treatment, Leqembi, in the latest attempt by the new CEO to trim costs. "We made good progress on the previous program that it amounts $1 billion of cost savings," Chief Executive Christopher Viehbacker said on a conference call to discuss the company's first-quarter earnings, adding that Tuesday's announcement was part of a new cost-saving effort. The U.S. biotech company said it will terminate two studies of an experimental neurological drug, and will also put on hold or scrap at least two more studies.
Investing.com -- Stocks in focus in premarket trade on Tuesday, April 25th. Please refresh for updates.
By Vlad Schepkov
Two great examples are Biogen (NASDAQ: BIIB) and Vertex Pharmaceuticals (NASDAQ: VRTX). Biogen is known for its blockbuster multiple sclerosis drugs, including top seller Tecfidera. Biogen's immunology drug, Rituxan, has also seen sales slip due to biosimilars in the market.